<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412644</url>
  </required_header>
  <id_info>
    <org_study_id>AP-CL-PSOR-PI-004893</org_study_id>
    <nct_id>NCT02412644</nct_id>
  </id_info>
  <brief_title>Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis</brief_title>
  <official_title>Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla®
      (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To evaluate the effectiveness of Otezla (apremilast®) in promoting
      maintenance of response in those subjects who obtained PASI-75 at week 12 of phototherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36</measure>
    <time_frame>36weeks</time_frame>
    <description>Analysis of Psoriasis Area Severity Index Score at week 36 to determine number of subjects who maintained PASI 75 at week 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Psoriasis Area Severity Index Score (PASI) 75 Response at Week 12</measure>
    <time_frame>12WEEKS</time_frame>
    <description>Psoriasis Area Severity Score of 75 or greater at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Psoriasis Area Severity Index Score 90 at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>PASI 90 or greater at week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Physician Global Assessment Score of 0 or 1 at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>PGA score 0 or 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Apremilast + apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apremilast + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apremilast</intervention_name>
    <arm_group_label>Apremilast + apremilast</arm_group_label>
    <arm_group_label>apremilast + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must meet the following criteria to be enrolled in this study:

          1. Male or female adult ≥ 18 years of age;

          2. Diagnosis of chronic plaque-type

          3. Moderate to severe plaque type psoriasis as defined at baseline by:

               -  PASI score of 12 or greater,

               -  PGA score of 3 or greater

               -  BSA affected by plaque-type psoriasis of 10% or greater,

          4. Able and willing to give written informed consent prior to performance of any
             study-related procedures

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from participation in this
        study:

          1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic,
             and/or guttate psoriasis) or drug induced psoriasis

          2. Subjects with previous exposure to apremilast

          3. Malignancy or history of malignancy, except for:

               -  treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;

               -  treated [ie, cured] malignancy with no evidence of recurrence within the previous
                  5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Bagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psoriasis Treatment Center of Central New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>March 2, 2017</results_first_submitted>
  <results_first_submitted_qc>December 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment May 28 2015-November 2015 through practice database</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Apremilast + Apremilast</title>
          <description>apremilast 30 mg BID for 12 weeks + apremilast 30 mg BID through week 36</description>
        </group>
        <group group_id="P2">
          <title>Apremilast + Placebo</title>
          <description>apremilast 30 mg BID for 12 weeks + placebo BID through week 36</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Apremilast + Apremilast</title>
          <description>apremilast + apremilast 30mg bid after week 12</description>
        </group>
        <group group_id="B2">
          <title>Apremilast + Placebo</title>
          <description>apremilast + Placebo bid after week 12</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="22"/>
                    <measurement group_id="B2" value="55" spread="38"/>
                    <measurement group_id="B3" value="47" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36</title>
        <description>Analysis of Psoriasis Area Severity Index Score at week 36 to determine number of subjects who maintained PASI 75 at week 36</description>
        <time_frame>36weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Apremilast</title>
            <description>apremilast + apremilast</description>
          </group>
          <group group_id="O2">
            <title>Apremilast + Placebo</title>
            <description>apremilast + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36</title>
          <description>Analysis of Psoriasis Area Severity Index Score at week 36 to determine number of subjects who maintained PASI 75 at week 36</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Psoriasis Area Severity Index Score (PASI) 75 Response at Week 12</title>
        <description>Psoriasis Area Severity Score of 75 or greater at week 12</description>
        <time_frame>12WEEKS</time_frame>
        <population>22 subjects completed week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast</title>
            <description>apremilast</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Psoriasis Area Severity Index Score (PASI) 75 Response at Week 12</title>
          <description>Psoriasis Area Severity Score of 75 or greater at week 12</description>
          <population>22 subjects completed week 12</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Psoriasis Area Severity Index Score 90 at Week 36</title>
        <description>PASI 90 or greater at week 36</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Apremilast</title>
            <description>apremilast 30 mg BID for 12 weeks + apremilast 30 mg BID through week 36</description>
          </group>
          <group group_id="O2">
            <title>Apremilast + Placebo</title>
            <description>apremilast 30 mg BID for 12 weeks + placebo BID through week 36</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Psoriasis Area Severity Index Score 90 at Week 36</title>
          <description>PASI 90 or greater at week 36</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Physician Global Assessment Score of 0 or 1 at Week 36</title>
        <description>PGA score 0 or 1</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Apremilast</title>
            <description>apremilast 30 mg BID for 12 weeks + apremilast 30 mg BID through week 36</description>
          </group>
          <group group_id="O2">
            <title>Apremilast + Placebo</title>
            <description>apremilast 30 mg BID for 12 weeks + placebo BID through week 36</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Physician Global Assessment Score of 0 or 1 at Week 36</title>
          <description>PGA score 0 or 1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Apremilast 30mg BID First 12 Weeks</title>
          <description>apremilast 30mg bid for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Apremilast 30mg BID After 12 Weeks</title>
          <description>apremilast bid after week 12</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID After 12 Weeks</title>
          <description>placebo bid after week 12</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>second degree burn</sub_title>
                <description>burn related NBUVB</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial rupture right leg</sub_title>
                <description>arterial rupture during catheterization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>First degree burn</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Bagel Director of Clinical Trials</name_or_title>
      <organization>Psoriasis Treatment Center of Central New Jersey</organization>
      <phone>6094434500</phone>
      <email>dreamacres1@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

